Aristeia Capital L.L.C. Makes New $422,000 Investment in Teleflex Incorporated (NYSE:TFX)

Aristeia Capital L.L.C. bought a new stake in Teleflex Incorporated (NYSE:TFX) during the second quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor bought 2,008 shares of the medical technology company’s stock, valued at approximately $422,000.

A number of other institutional investors have also modified their holdings of TFX. Oregon Public Employees Retirement Fund increased its holdings in Teleflex by 1.2% in the second quarter. Oregon Public Employees Retirement Fund now owns 4,021 shares of the medical technology company’s stock valued at $846,000 after buying an additional 46 shares during the last quarter. Crossmark Global Holdings Inc. raised its position in shares of Teleflex by 1.9% during the 2nd quarter. Crossmark Global Holdings Inc. now owns 2,779 shares of the medical technology company’s stock valued at $584,000 after acquiring an additional 53 shares in the last quarter. KBC Group NV lifted its stake in Teleflex by 1.8% during the fourth quarter. KBC Group NV now owns 3,173 shares of the medical technology company’s stock worth $791,000 after purchasing an additional 55 shares during the last quarter. Empirical Finance LLC boosted its holdings in Teleflex by 3.9% in the first quarter. Empirical Finance LLC now owns 1,564 shares of the medical technology company’s stock worth $354,000 after purchasing an additional 58 shares during the period. Finally, SRS Capital Advisors Inc. increased its stake in Teleflex by 0.3% during the second quarter. SRS Capital Advisors Inc. now owns 19,527 shares of the medical technology company’s stock valued at $4,107,000 after purchasing an additional 62 shares during the last quarter. Institutional investors and hedge funds own 95.62% of the company’s stock.

Insider Buying and Selling at Teleflex

In other news, Director Stuart A. Randle sold 2,674 shares of the company’s stock in a transaction that occurred on Friday, August 16th. The shares were sold at an average price of $238.93, for a total value of $638,898.82. Following the completion of the sale, the director now directly owns 5,496 shares of the company’s stock, valued at approximately $1,313,159.28. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. 1.43% of the stock is owned by corporate insiders.

Teleflex Stock Performance

TFX opened at $245.90 on Wednesday. The company has a current ratio of 2.58, a quick ratio of 1.44 and a debt-to-equity ratio of 0.36. The business’s 50 day moving average is $236.19 and its 200-day moving average is $220.74. The stock has a market cap of $11.59 billion, a PE ratio of 39.47, a price-to-earnings-growth ratio of 2.22 and a beta of 1.16. Teleflex Incorporated has a twelve month low of $177.63 and a twelve month high of $257.85.

Teleflex (NYSE:TFX) last announced its earnings results on Thursday, August 1st. The medical technology company reported $3.42 earnings per share for the quarter, beating the consensus estimate of $3.33 by $0.09. Teleflex had a return on equity of 14.51% and a net margin of 8.76%. The firm had revenue of $749.70 million for the quarter, compared to the consensus estimate of $762.98 million. During the same quarter in the previous year, the business earned $3.41 EPS. The firm’s revenue for the quarter was up .9% on a year-over-year basis. On average, analysts predict that Teleflex Incorporated will post 13.97 earnings per share for the current year.

Teleflex Announces Dividend

The business also recently announced a quarterly dividend, which was paid on Monday, September 16th. Investors of record on Thursday, August 15th were given a $0.34 dividend. The ex-dividend date was Thursday, August 15th. This represents a $1.36 dividend on an annualized basis and a yield of 0.55%. Teleflex’s dividend payout ratio is presently 21.83%.

Wall Street Analysts Forecast Growth

A number of research firms have recently issued reports on TFX. Piper Sandler upgraded shares of Teleflex from a “neutral” rating to an “overweight” rating and raised their price target for the stock from $205.00 to $245.00 in a research report on Monday, July 1st. Royal Bank of Canada raised their target price on shares of Teleflex from $235.00 to $260.00 and gave the stock an “outperform” rating in a report on Friday, August 2nd. Truist Financial upped their target price on Teleflex from $240.00 to $247.00 and gave the company a “hold” rating in a report on Monday, August 5th. Finally, Stephens increased their price target on Teleflex from $275.00 to $290.00 and gave the stock an “overweight” rating in a research report on Friday, August 2nd. Three analysts have rated the stock with a hold rating and six have given a buy rating to the company’s stock. Based on data from MarketBeat.com, the company has an average rating of “Moderate Buy” and an average target price of $265.57.

Teleflex Profile

Teleflex Incorporated designs, develops, manufactures, and supplies single-use medical devices for common diagnostic and therapeutic procedures in critical care and surgical applications worldwide. The company provides vascular access products that comprise Arrow branded catheters, catheter navigation and tip positioning systems, and intraosseous access systems for the administration of intravenous therapies, the measurement of blood pressure, and the withdrawal of blood samples through a single puncture site.